[持久的左心室辅助装置治疗患者之前的MitraClip或Impella干预]
Tomoki Ushijima1, Takeo Fujino, Shogo Matsunaga
1Department of Advanced Cardiopulmonary Failure, Kyushu University, Fukuoka, Japan.
Kyobu geka. The Japanese journal of thoracic surgery
|June 10, 2025
概括
在之前接受过Impella或MitraClip治疗的患者中,持久左心室辅助装置 (LVAD) 植入的结果显示了可管理的风险. 仔细的评估对于开发这些复杂病例的有效治疗策略至关重要.
科学领域:
- 心脏病学 心脏病学
- 心血管外科心血管外科
- 医疗器械 医疗器械
背景情况:
- 左心室辅助装置 (LVAD) 治疗是晚期心力衰竭的关键治疗方法.
- 之前使用Impella (Abiomed) 或MitraClip (Abbott) 的干预可能会对随后的LVAD植入带来独特的挑战.
- 使用Impella与潜在的de novo大动脉缺陷 (AI) 有关,而MitraClip可以在LVAD支持下引起血液动力学问题.
研究的目的:
- 为了评估持久的LVAD植入在患有Impella或MitraClip手术史的患者的结果.
- 为了确定潜在的并发症,并评估LVAD治疗在这个特定患者群体中的安全性和有效性.
主要方法:
- 对17名先前接受Impella支持的患者和5名先前接受MitraClip植入的患者进行了回顾性分析,这些患者正在接受持久的LVAD治疗.
- 详细审查手术干预措施,包括大动脉膜整形和中枢置换.
- 术后并发症的评估,特别是大动脉衰竭和血液动力学稳定性.
主要成果:
- 在17名Impella后患者中,7人需要在LVAD植入期间进行大动脉膜整形,1人需要进行AI进展的外科手术.
- 在9名非干预性Impella后患者中,1名中度AI患者接受了心脏移植;其他人有轻度AI.
- 在MitraClip后的5名患者中,有4名在LVAD植入期间进行了心心膜置换;剩下的患者在血液动力学上保持稳定.
结论:
- 持久的LVAD植入是可行的在患者之前的Impella或MitraClip干预措施,虽然需要考虑AI和血液动力学障碍等特定的并发症.
- 基于彻底的手术前评估的个性化治疗策略对于优化结果至关重要.
- 这些先前干预的日益普遍性需要进一步的研究,并为该队列的LVAD治疗制定了指南.
相关概念视频
Cardiomyopathy V: Interprofessional Care
2
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
2
Cardiomyopathy II: Dilated Cardiomyopathy
1
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
1
Heart Failure VI: Adjunct Therapies
5
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
5
Mitral Valve Prolapse II: Assessment and Management
3
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
3


